JOSEPH SHEMWELL: Open Payments
NPI 1710505391 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,813 in 110 payments from 21 companies in 2025. Trend: 2023 $1,479 · 2024 $2,100 · 2025 $1,813
Food & beverage: $1,813
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $585 |
| Janssen Biotech, Inc. | 9 | $165 |
| Ardelyx, Inc. | 6 | $154 |
| Madrigal Pharmaceuticals | 5 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
| Lilly USA, LLC | 6 | $98 |
| Aimmune Therapeutics, Inc. | 4 | $77 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $74 |
| Phathom Pharmaceuticals, Inc. | 5 | $52 |
| Ipsen Biopharmaceuticals, Inc | 3 | $51 |
Products named: RINVOQ, TREMFYA, IBSRELA, REZDIFFRA, ENTYVIO, SKYRIZI, OMVOH, LINZESS.
Industry payments across MS — which companies pay providers there.
